Cargando…
Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
INTRODUCTION: The aim of this work was to assess the impact of prolonged low immunoglobulin (IgG or IgM) serum concentrations on the potential cumulative serious infection (SI) risk in pediatric patients following rituximab treatment for granulomatosis with polyangiitis or microscopic polyangiitis (...
Autores principales: | Melega, Simone, Brogan, Paul, Cleary, Gavin, Hersh, Aimee O., Kasapcopur, Ozgur, Rangaraj, Satyapal, Yeung, Rae S. M., Zeft, Andrew, Cooper, Jennifer, Pordeli, Pooneh, Kirchner, Petra, Lehane, Patricia B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964878/ https://www.ncbi.nlm.nih.gov/pubmed/35279811 http://dx.doi.org/10.1007/s40744-022-00433-0 |
Ejemplares similares
-
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021) -
Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis
por: Jamois, Candice, et al.
Publicado: (2022) -
Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021) -
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
por: Geetha, Duvuru, et al.
Publicado: (2014) -
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Shah, Shivani, et al.
Publicado: (2015)